모아라이프플러스

142760KOSDAQ자연과학 및 공학 연구개발업

67.3 / 100

Reference Date: 2026-04-13

Financial Score22.5 / 40

News Sentiment18.8 / 25

Momentum14.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Surged 61.8% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Moalifeplus focuses on biopharmaceutical R&D using proprietary technologies (HumaMAX, MucoMAX), alongside consumer businesses such as health functional foods, cosmetics, and pet care products. Its γ-PGA-based functional ingredients are approved by the Korean FDA and the U.S. FDA, enabling global expansion through partnerships with Swiss companies and overseas exports of skincare brands.

Number of Employees

54people

Average Salary

39.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

1.46Industry Average 3.827.0Point

Half of industry avg (excellent)

ROE

-36.73Industry Average -32.113.5Point

In line with industry avg

Debt Ratio

1.91Industry Average 7.528.0Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼21.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼12.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -13.1% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 75

Positive
모아라이프플러스, 비만치료 '근손실' 대응 EL-32 비임상 본격화
모아라이프플러스는 비만치료제 시장의 근손실 문제에 대응하기 위한 후보물질 'EL-32'의 비임상 연구를 미국 NorthStrive Biosciences를 통해 본격화했습니다.
Positive
모아라이프플러스, 비만치료제 근육 감소 연구 공식 착수
모아라이프플러스는 자사가 기술이전한 근육 조절 기반 파이프라인 BLS-M32(EL-32)가 미국 NorthStrive Biosciences를 통해 비임상 연구 단계에 공식 착수했다고 밝혔습니다.

Detailed Momentum

52-week position3.0Point

52w lower range (27%)

Current 1,060Won52-week high 2,19052-week low 622

1-month return6.0Point

1m +61.83% (strong rise)

Volume trend5.0Point

Volume flat

Detailed Disclosure

11 totalPositive 1Neutral 10Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-04-09
Positive[기재정정]최대주주변경을수반하는주식담보제공계약체결2026-04-09
Neutral정기주주총회결과2026-03-31
Neutral전환사채(해외전환사채포함)발행후만기전사채취득2026-03-30
Neutral소액공모실적보고서2026-03-24